{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lepland A"],"funding":["Eesti Teadusagentuur","Università di Padova","Estonian Research Council","Estonian Research Agency","Ramon y Cajal","MSCA-RISE 2018 Project OXIGENATED, and EuronanomedIII","\"ERDF A way of making Europe\"","Royal Society of Chemistry","MICIN/AEIMCIN/AEI /10.13039/501100011033/","CIBER BBN"],"pagination":["e2410288"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11904948"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(10)"],"pubmed_abstract":["In triple-negative breast cancer (TNBC), pro-tumoral macrophages promote metastasis and suppress the immune response. To target these cells, a previously identified CD206 (mannose receptor)-binding peptide, mUNO was engineered to enhance its affinity and proteolytic stability. The new rationally designed peptide, MACTIDE, includes a trypsin inhibitor loop, from the Sunflower Trypsin Inhibitor-I. Binding studies to recombinant CD206 revealed a 15-fold lower K<sub>D</sub> for MACTIDE compared to parental mUNO. Mass spectrometry further demonstrated a 5-fold increase in MACTIDE's half-life in tumor lysates compared to mUNO. Homing studies in TNBC-bearing mice shows that fluorescein (FAM)-MACTIDE precisely targeted CD206<sup>+</sup> tumor-associated macrophages (TAM) upon intravenous, intraper"],"journal":["Advanced science (Weinheim, Baden-Wurttemberg, Germany)"],"pubmed_title":["Peptide-Drug Conjugate for Therapeutic Reprogramming of Tumor-Associated Macrophages in Breast Cancer."],"pmcid":["PMC11904948"],"funding_grant_id":["PRG230","CB06/01/0074","PRG1788","DiSCOG MARI_BIRD22_01","R21-6405053838","PSG38","RYC2020-028754-I","R21‐6405053838","PID2021-122364OA-I00","PRG2011"],"pubmed_authors":["Crespi-Amer M","Royo M","Lombardia M","Marigo I","Scodeller P","Acosta G","Lepland A","Peranzoni E","Asciutto EK","Peterson P","Teesalu T","Modesti L","Haljasorg U","Kilk K"],"additional_accession":[]},"is_claimable":false,"name":"Peptide-Drug Conjugate for Therapeutic Reprogramming of Tumor-Associated Macrophages in Breast Cancer.","description":"In triple-negative breast cancer (TNBC), pro-tumoral macrophages promote metastasis and suppress the immune response. To target these cells, a previously identified CD206 (mannose receptor)-binding peptide, mUNO was engineered to enhance its affinity and proteolytic stability. The new rationally designed peptide, MACTIDE, includes a trypsin inhibitor loop, from the Sunflower Trypsin Inhibitor-I. Binding studies to recombinant CD206 revealed a 15-fold lower K<sub>D</sub> for MACTIDE compared to parental mUNO. Mass spectrometry further demonstrated a 5-fold increase in MACTIDE's half-life in tumor lysates compared to mUNO. Homing studies in TNBC-bearing mice shows that fluorescein (FAM)-MACTIDE precisely targeted CD206<sup>+</sup> tumor-associated macrophages (TAM) upon intravenous, intraper","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-06-03T02:30:46.414Z","creation":"2025-04-04T00:32:25.983Z"},"accession":"S-EPMC11904948","cross_references":{"pubmed":["39840532"],"doi":["10.1002/advs.202410288"]}}